Aim: Glioblastoma is the most common and highest-grade infiltrative astrocytoma. It is usually associated with a bad prognosis. Histological grading is highly predictive of an aggressive behavior, with a mean survival rate of 1 year. Nonetheless, individual patient survival can vary substantially, ranging from 1 month to over 5 years. Several distinct clinical parameters and molecular alterations have recently been described in glioblastoma. The present study compares clinical, radiologic and therapeutic parameters in a series of glioblastomas to identify prognostic factors.
Material And Methods: We evaluated 50 cases who were operated on for intracranial glioblastoma between January 1998-March 2004 retrospectively. All clinical records, radiological records and management modalities were evaluated as prognostic value.
Results: The mean survival time was 7.5 months (range, 1-18 months). We confirmed the patients' age, gender, Karnofsky Performance Scale score at discharge, postoperative radiotherapy and reoperation as decisive prognostic factors after multivariate analyses.
Conclusion: We could show that some clinical parameters and treatment modalities were associated with prognosis. Younger age, male gender, higher Karnofsky Performance Score at discharge, total surgical resection, radiotherapy and reoperation were predictor for better prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5137/1019-5149.JTN.2461-09.4 | DOI Listing |
Anticancer Agents Med Chem
January 2025
Cancer Center, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China.
Dysregulated lipid metabolism within the tumor microenvironment (TME) is a critical hallmark of cancer progression, with lipids serving as a major energy source for tumor cells. Beyond their role in cell membrane synthesis, lipids also provide essential substrates for biomolecule production and activate signaling pathways that regulate various cellular processes. Aberrant lipid metabolism impacts not only function but also alters the behavior of immune and stromal cells within the TME.
View Article and Find Full Text PDFAnticancer Agents Med Chem
January 2025
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Lung cancer is correlated with a high death rate, with approximately 1.8 million mortality cases reported worldwide in 2022. Despite development in the control of lung cancer, most cases are detected at higher stages with short survival rates.
View Article and Find Full Text PDFAfr J Reprod Health
November 2024
Department of Obstetrics and Gynecology, Wuxi No.2 People's Hospital, Wuxi 214002, Jiangsu Province, China.
Cervical cancer (CC) is a malignant tumor in females characterized by high incidence and mortality rates, often resulting in a poor prognosis for patients. Zoledronic acid (ZA), a third-generation bisphosphonate, exhibits anti-tumor properties across various types of tumors. To further understand the effect of ZA in the treatment of CC, this article included two kinds of human CC cells (CCCs) as the research object, examining the impact of varying levels of ZA on the cells' biological properties.
View Article and Find Full Text PDFCancer Commun (Lond)
January 2025
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, P. R. China.
Background: Hormone receptor-positive (HR+)/humaal growth factor receptor 2-negative (HER2-) breast cancer, the most common breast cancer type, has variable prognosis and high recurrence risk. Neoadjuvant therapy is recommended for median-high risk HR+/HER2- patients. This phase II, single-arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2- breast cancer patients.
View Article and Find Full Text PDFAsia Pac J Clin Oncol
January 2025
Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Purpose: Our study aims to evaluate the characteristics of serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) levels and their correlations with immune status and prognosis in advanced lung cancer patients.
Methods: Patients diagnosed with advanced lung cancer based on histology or cytology in Peking University People's Hospital from July 2020 to November 2021 were enrolled. Clinicopathological data were recorded and analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!